Quality Of Life While Receiving Faslodex

AstraZeneca

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT00643513

NIS-ORU-FAS-2007/1

Details and patient eligibility

About

To study QoL related response, symptom spectrum and severity in disseminated breast cancer patients receiving Faslodex hormonal therapy.

Enrollment: 120 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologic and/or cytological proven breast cancer.
• Patients with metastases of breast cancer ± postmenopausal primary tumor ≥12 months.
• Positive oestrogen receptors (ER+), positive progesterone receptors (PgR+) or unknown hormonal receptors (if duration between surgery and metastasis occurring is not less 2 years) which are indirect confirmation of hormone sensitive tumor.
• ECOG performance status of ≤ 2
• Patient willingness to take part in the programm
• Life expectancy of more than 6 months.
• Patient ability to complete a questionnaire.

Exclusion criteria

• Contraindications for Faslodex therapy
• Other anticancer therapy (chemotherapy, hormonal therapy with other drugs, radiotherapy), except for radiotherapy of sites which are not only measurable or evaluable manifestation of disease.